Latest Breaking News On - Pliant therapeutics daily - Page 8 : comparemela.com

Pliant Therapeutics, Inc (NASDAQ:PLRX) General Counsel Sells $230,131 78 in Stock

Pliant Therapeutics, Inc (NASDAQ:PLRX) General Counsel Sells $230,131 78 in Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesRobertw bairdMike ouimetteCantor fitzgeraldPliant therapeutics incVanguard group incCanaccord genuity groupSecurities exchange commissionNeedham companyBlackrock incPricet rowe associates incPliant therapeuticsGet free reportGeneral counsel mike ouimetteExchange commissionGenuity group

FY2024 Earnings Estimate for Pliant Therapeutics, Inc (NASDAQ:PLRX) Issued By Cantor Fitzgerald

FY2024 Earnings Estimate for Pliant Therapeutics, Inc (NASDAQ:PLRX) Issued By Cantor Fitzgerald
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United statesRobertw bairdGranahan investment managementPliant therapeutics incTekla capital managementCanaccord genuity groupCitigroup incNeedham companyCantor fitzgeraldPliant therapeuticsFree reportPliant therapeuticGet free reportCapital managementHill capital managementInvestment management

Pliant Therapeutics (NASDAQ:PLRX) Trading 2 2% Higher

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) shares traded up 2.2% on Thursday . The company traded as high as $18.24 and last traded at $18.21. 426,095 shares were traded during trading, a decline of 52% from the average session volume of 881,966 shares. The stock had previously closed at $17.81. Wall Street Analysts Forecast […]

United statesTopco ltdAcadian asset managementDimensional fund advisorsTower research capitalPliant therapeutics incJpmorgan chase coPliant therapeutics company profileRoyal bankCanaccord genuity groupPliant therapeuticsFree reportAsset managementFund advisorsResearch capitalPliant therapeutics daily

Brokerages Set Pliant Therapeutics, Inc (NASDAQ:PLRX) Price Target at $47 83

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) has been assigned an average recommendation of “Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat.com reports. Eleven research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have covered the stock in the last year […]

United statesRobertw bairdMike ouimetteTower research capitalPliant therapeutics incCantor fitzgeraldAcadian asset managementNeedham companyPliant therapeutics company profileTopco ltdDimensional fund advisorsPliant therapeuticsFree reportGeneral counsel mike ouimetteAsset managementFund advisors

Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5%

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) shares dropped 5% on Monday . The company traded as low as $19.68 and last traded at $19.79. Approximately 266,692 shares changed hands during trading, a decline of 69% from the average daily volume of 857,019 shares. The stock had previously closed at $20.84. Wall Street Analysts Forecast […]

Nova scotiaUnited statesEric lefebvreBernard couliePliant therapeutics incRoyal bankCanaccord genuity groupDeutsche bankVanguard group incPricet rowe associates incCantor fitzgeraldBlackrock incFred alger managementPliant therapeuticsGet ratingTherapeutics trading down